Algeria Meningococcal Vaccines Market Size & Outlook
Algeria meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
Algeria meningococcal vaccines market highlights
- The Algeria meningococcal vaccines market generated a revenue of USD 0.4 million in 2021 and is expected to reach USD 0.7 million by 2030.
- The Algeria market is expected to grow at a CAGR of 8.2% from 2022 to 2030.
- In terms of segment, bivalent was the largest revenue generating type in 2021.
- Quadrivalent is the most lucrative type segment registering the fastest growth during the forecast period.
Meningococcal vaccines market data book summary
| Market revenue in 2021 | USD 0.4 million |
| Market revenue in 2030 | USD 0.7 million |
| Growth rate | 8.2% (CAGR from 2021 to 2030) |
| Largest segment | Bivalent |
| Fastest growing segment | Quadrivalent |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Turkey meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2030.
- Morocco is the fastest growing regional market in Middle East & Africa and is projected to reach USD 0.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Algeria meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Bivalent was the largest segment with a revenue share of 25% in 2021. Horizon Databook has segmented the Algeria meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
High incidence of meningococcal in the country and neighboring countries increases the risk of meningococcal outbreak. The incidence of IMD is approximately 0.07 cases per 100,000 population, and MenB is most diagnosed serogroup in the country. Moreover, increasing healthcare spending in the country may fuel market growth.
The country spends around 6.2% of its total GDP on the healthcare sector. Meningococcal vaccine is not included in the country’s National Immunization Program. However, its is recommended for high-risk groups. Moreover, Men ACWY polysaccharide vaccination is recommended for Hajj pilgrims, as well as during COVID-19 pandemic.
Moreover, MenAfriVac initiative in the region has significantly reduced the prevalence of meningitis in the country. The market in Algeria is dominated by international players such as Sanofi and GlaxoSmithKline plc., among other.
Reasons to subscribe to Algeria meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Algeria meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Algeria meningococcal vaccines market , including forecasts for subscribers. This country databook contains high-level insights into Algeria meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Algeria meningococcal vaccines market size, by type, 2018-2030 (US$M)
Algeria Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
